Renovaro Interest Expense vs Research Development Analysis

RENB Stock

0.69 0.08 12.95%

Renovaro Biosciences financial indicator trend analysis is much more than just breaking down Renovaro Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Renovaro Biosciences is a good investment. Please check the relationship between Renovaro Biosciences Interest Expense and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.

Interest Expense vs Research Development

Interest Expense vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Renovaro Biosciences Interest Expense account and Research Development. At this time, the significance of the direction appears to have weak relationship.

The correlation between Renovaro Biosciences' Interest Expense and Research Development is 0.32. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Research Development in the same time period over historical financial statements of Renovaro Biosciences, assuming nothing else is changed. The correlation between historical values of Renovaro Biosciences' Interest Expense and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of Renovaro Biosciences are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Interest Expense i.e., Renovaro Biosciences' Interest Expense and Research Development go up and down completely randomly.

Correlation Coefficient

0.32

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Research Development

Most indicators from Renovaro Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Renovaro Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.The current year's Selling General Administrative is expected to grow to about 25.4 M, whereas Tax Provision is forecasted to decline to 0.00.

Renovaro Biosciences fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Common Stock Total Equity	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Short Long Term Debt Total	Net Debt	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Current Assets	Short Term Debt	Non Current Assets Total	Non Currrent Assets Other	Intangible Assets	Net Tangible Assets	Accounts Payable	Other Assets	Retained Earnings Total Equity	Capital Surpluse
Other Current Liab		0.97	0.22	-0.83	0.6	0.77	0.81	0.93	0.27	0.06	0.4	-0.27	-0.27	0.74	0.85	-0.21	-0.18	0.54	0.32	-0.18	-0.27	-0.5	0.93	-0.2	-0.43	0.33
Total Current Liabilities	0.97		0.19	-0.91	0.65	0.81	0.81	0.95	0.24	0.1	0.47	-0.31	-0.31	0.83	0.88	-0.25	-0.22	0.72	0.3	-0.2	-0.28	-0.61	0.98	-0.19	-0.5	0.38
Total Stockholder Equity	0.22	0.19		-0.33	0.77	0.67	0.63	0.48	1.0	0.89	-0.6	0.76	0.76	0.05	0.56	0.72	0.8	0.02	0.99	0.54	0.87	0.02	0.14	0.44	-0.75	0.87
Retained Earnings	-0.83	-0.91	-0.33		-0.83	-0.91	-0.8	-0.92	-0.37	-0.37	-0.37	0.11	0.11	-0.91	-0.94	0.13	0.02	-0.82	-0.42	0.18	0.07	0.58	-0.89	0.13	0.74	-0.64
Common Stock Total Equity	0.6	0.65	0.77	-0.83		0.97	0.84	0.83	0.79	0.8	-0.11	0.41	0.41	0.62	0.92	0.34	0.48	0.57	0.81	0.17	0.49	-0.32	0.6	0.2	-0.96	0.92
Other Stockholder Equity	0.77	0.81	0.67	-0.91	0.97		0.92	0.94	0.71	0.65	0.03	0.23	0.23	0.72	0.98	0.21	0.31	0.63	0.74	0.1	0.31	-0.44	0.77	0.09	-0.88	0.83
Total Liab	0.81	0.81	0.63	-0.8	0.84	0.92		0.91	0.68	0.54	-0.04	0.22	0.22	0.64	0.89	0.36	0.3	0.51	0.71	0.18	0.25	-0.59	0.77	0.11	-0.68	0.68
Common Stock	0.93	0.95	0.48	-0.92	0.83	0.94	0.91		0.52	0.38	0.24	-0.03	-0.03	0.77	0.97	-0.01	0.06	0.65	0.57	-0.03	0.03	-0.52	0.92	-0.05	-0.7	0.62
Total Assets	0.27	0.24	1.0	-0.37	0.79	0.71	0.68	0.52		0.89	-0.57	0.74	0.74	0.1	0.59	0.71	0.78	0.06	1.0	0.53	0.84	-0.04	0.19	0.43	-0.76	0.89
Short Long Term Debt Total	0.06	0.1	0.89	-0.37	0.8	0.65	0.54	0.38	0.89		-0.55	0.79	0.79	0.16	0.52	0.72	0.81	0.19	0.88	0.5	0.87	-0.04	0.05	0.55	-0.84	0.91
Net Debt	0.4	0.47	-0.6	-0.37	-0.11	0.03	-0.04	0.24	-0.57	-0.55		-0.89	-0.89	0.5	0.2	-0.81	-0.88	0.5	-0.52	-0.75	-0.79	-0.42	0.52	-0.45	0.09	-0.3
Cash	-0.27	-0.31	0.76	0.11	0.41	0.23	0.22	-0.03	0.74	0.79	-0.89		1.0	-0.31	0.08	0.85	0.99	-0.28	0.7	0.54	0.9	0.37	-0.39	0.47	-0.45	0.57
Cash And Short Term Investments	-0.27	-0.31	0.76	0.11	0.41	0.23	0.22	-0.03	0.74	0.79	-0.89	1.0		-0.31	0.08	0.85	0.99	-0.28	0.7	0.54	0.9	0.37	-0.39	0.47	-0.45	0.57
Net Receivables	0.74	0.83	0.05	-0.91	0.62	0.72	0.64	0.77	0.1	0.16	0.5	-0.31	-0.31		0.77	-0.26	-0.23	0.8	0.14	-0.25	-0.29	-0.66	0.82	-0.18	-0.55	0.41
Common Stock Shares Outstanding	0.85	0.88	0.56	-0.94	0.92	0.98	0.89	0.97	0.59	0.52	0.2	0.08	0.08	0.77		0.05	0.16	0.68	0.63	-0.05	0.15	-0.45	0.84	0.01	-0.84	0.74
Non Current Liabilities Total	-0.21	-0.25	0.72	0.13	0.34	0.21	0.36	-0.01	0.71	0.72	-0.81	0.85	0.85	-0.26	0.05		0.85	-0.28	0.68	0.62	0.83	-0.02	-0.3	0.53	-0.32	0.49
Total Current Assets	-0.18	-0.22	0.8	0.02	0.48	0.31	0.3	0.06	0.78	0.81	-0.88	0.99	0.99	-0.23	0.16	0.85		-0.22	0.74	0.53	0.89	0.32	-0.3	0.46	-0.51	0.62
Short Term Debt	0.54	0.72	0.02	-0.82	0.57	0.63	0.51	0.65	0.06	0.19	0.5	-0.28	-0.28	0.8	0.68	-0.28	-0.22		0.09	-0.27	-0.24	-0.62	0.75	-0.01	-0.54	0.4
Non Current Assets Total	0.32	0.3	0.99	-0.42	0.81	0.74	0.71	0.57	1.0	0.88	-0.52	0.7	0.7	0.14	0.63	0.68	0.74	0.09		0.51	0.81	-0.08	0.24	0.41	-0.77	0.89
Non Currrent Assets Other	-0.18	-0.2	0.54	0.18	0.17	0.1	0.18	-0.03	0.53	0.5	-0.75	0.54	0.54	-0.25	-0.05	0.62	0.53	-0.27	0.51		0.62	0.0	-0.19	0.52	-0.07	0.32
Intangible Assets	-0.27	-0.28	0.87	0.07	0.49	0.31	0.25	0.03	0.84	0.87	-0.79	0.9	0.9	-0.29	0.15	0.83	0.89	-0.24	0.81	0.62		0.25	-0.31	0.54	-0.55	0.68
Net Tangible Assets	-0.5	-0.61	0.02	0.58	-0.32	-0.44	-0.59	-0.52	-0.04	-0.04	-0.42	0.37	0.37	-0.66	-0.45	-0.02	0.32	-0.62	-0.08	0.0	0.25		-0.67	0.07	0.19	-0.21
Accounts Payable	0.93	0.98	0.14	-0.89	0.6	0.77	0.77	0.92	0.19	0.05	0.52	-0.39	-0.39	0.82	0.84	-0.3	-0.3	0.75	0.24	-0.19	-0.31	-0.67		-0.27	-0.45	0.35
Other Assets	-0.2	-0.19	0.44	0.13	0.2	0.09	0.11	-0.05	0.43	0.55	-0.45	0.47	0.47	-0.18	0.01	0.53	0.46	-0.01	0.41	0.52	0.54	0.07	-0.27		-0.23	0.31
Retained Earnings Total Equity	-0.43	-0.5	-0.75	0.74	-0.96	-0.88	-0.68	-0.7	-0.76	-0.84	0.09	-0.45	-0.45	-0.55	-0.84	-0.32	-0.51	-0.54	-0.77	-0.07	-0.55	0.19	-0.45	-0.23		-0.92
Capital Surpluse	0.33	0.38	0.87	-0.64	0.92	0.83	0.68	0.62	0.89	0.91	-0.3	0.57	0.57	0.41	0.74	0.49	0.62	0.4	0.89	0.32	0.68	-0.21	0.35	0.31	-0.92

Click cells to compare fundamentals

Renovaro Biosciences Account Relationship Matchups

Renovaro Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	470.6K	1.3M	3.6M	723.2K	17.9M	18.8M
Total Current Liabilities	1.3M	1.9M	6.5M	11.0M	30.3M	31.8M
Total Stockholder Equity	166.3M	174.7M	72.6M	46.5M	132.0M	78.5M
Retained Earnings	(64.2M)	(90.9M)	(204.3M)	(244.0M)	(324.7M)	(308.4M)
Common Stock Total Equity	3.6K	4.5K	4.7K	5.2K	6.0K	6.3K
Other Stockholder Equity	230.5M	265.6M	277.0M	290.6M	456.8M	479.7M
Total Liab	11.8M	14.9M	12.0M	11.8M	31.2M	32.7M
Common Stock	4.7K	5.2K	5.3K	6.4K	15.5K	16.3K
Total Assets	178.1M	189.6M	84.6M	58.3M	163.1M	88.6M
Net Debt	(1.1M)	(13.4M)	(2.2M)	3.7M	3.6M	3.7M
Cash	8.7M	20.7M	9.2M	1.9M	220.5K	209.4K
Cash And Short Term Investments	8.7M	20.7M	9.2M	1.9M	220.5K	209.4K
Net Receivables	20.8K	2.0K	1.6K	1.1M	1.3M	1.3M
Common Stock Shares Outstanding	46.3M	47.2M	52.5M	56.3M	96.2M	101.1M
Liabilities And Stockholders Equity	178.1M	189.6M	84.6M	58.3M	163.1M	88.6M
Non Current Liabilities Total	10.5M	13.1M	5.6M	775.6K	842.4K	800.3K
Total Current Assets	8.9M	20.9M	9.6M	2.6M	2.0M	1.9M
Short Term Debt	271.3K	292.4K	1.5M	5.0M	2.9M	3.1M
Non Current Assets Total	169.2M	168.7M	75.1M	55.7M	161.1M	96.5M
Non Currrent Assets Other	137.6K	21.0K	68.6K	21.7K	19.8K	18.9K
Accumulated Other Comprehensive Income	(41.4K)	(10.8K)	(30.4K)	(29.9K)	(170.8K)	(162.3K)
Intangible Assets	154.9M	154.9M	61.6M	42.7M	30.0K	28.5K
Net Tangible Assets	(269.1K)	8.1M	(636.4K)	(7.8M)	(7.0M)	(6.7M)
Accounts Payable	592.9K	320.6K	1.4M	5.3M	9.4M	9.9M
Other Current Assets	242.9K	232.9K	393.0K	690.9K	668.9K	362.8K
Other Liab	22.9M	5.7M	3.2M	6.0M	5.4M	6.0M
Capital Lease Obligations	1.8M	1.5M	1.2M	969.0K	1.1M	871.1K
Net Invested Capital	172.1M	180.4M	78.4M	51.1M	46.0M	43.7M
Property Plant And Equipment Gross	2.5M	2.2M	2.1M	1.9M	2.2M	1.5M
Non Current Liabilities Other	22.9M	5.7M	3.2M	6.0M	5.4M	6.0M
Net Working Capital	7.6M	19.0M	3.1M	(8.5M)	(7.6M)	(7.2M)
Property Plant Equipment	2.5M	2.2M	1.7M	1.4M	1.6M	1.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Renovaro Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renovaro Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renovaro Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renovaro Biosciences Stock:

How To Invest In Renovaro

Details

Is Renovaro Stock a good investment?

Details

What is Renovaro Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.98)

Return On Assets

(0.15)

Return On Equity

(0.90)

The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Renovaro Interest Expense vs Research Development Analysis

Interest Expense vs Research Development

Interest Expense vs Research Development Correlation Analysis

Correlation Coefficient

Interest Expense

Research Development

Renovaro Biosciences fundamental ratios Correlations

Renovaro Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Renovaro Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Non Current Assets Total	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Retained Earnings Total Equity	- 0.96	Common Stock Total Equity
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Capital Surpluse	- 0.92	Retained Earnings Total Equity
Common Stock	- 0.92	Retained Earnings
Net Receivables	- 0.91	Retained Earnings
Other Stockholder Equity	- 0.91	Retained Earnings